First Time Loading...

Adamis Pharmaceuticals Corp
NASDAQ:ADMP

Watchlist Manager
Adamis Pharmaceuticals Corp Logo
Adamis Pharmaceuticals Corp
NASDAQ:ADMP
Watchlist
Price: 0.4901 USD -2.97%
Updated: May 8, 2024
Section:
 

Wall Street
Price Targets

ADMP Price Targets Summary
Adamis Pharmaceuticals Corp

Wall Street analysts forecast ADMP stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADMP is 0.42 USD .

ADMP Lowest Forecast
Wall Street Target
Not Available
ADMP Average Forecast
Wall Street Target
0.42 USD
14% Downside
ADMP Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
0.42 USD
14% Downside
Highest
Price Target
Not Available
Adamis Pharmaceuticals Corp Competitors:
Price Targets
002900
Harbin Medisan Pharmaceutical Co Ltd
55% Upside
LABB
Genomma Lab Internacional SAB de CV
2% Downside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
13% Downside
S
012790
Sinil Pharmaceutical Co Ltd
187% Upside
002900
Harbin Medisan Pharmaceutical Co Ltd
55% Upside
LABB
Genomma Lab Internacional SAB de CV
2% Downside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
13% Downside
S
012790
Sinil Pharmaceutical Co Ltd
187% Upside
ROG
Roche Holding AG
26% Upside
600557
Jiangsu Kanion Pharmaceutical Co Ltd
29% Upside
INDOCO
Indoco Remedies Ltd
17% Upside
T
TSPC
Tempo Scan Pacific Tbk PT
15% Downside

Revenue
Forecast

Revenue Estimate
Adamis Pharmaceuticals Corp

For the last 1 year the compound annual growth rate for Adamis Pharmaceuticals Corp's revenue is 115%. The projected CAGR for the next 1 year is 93%.

115%
Past Growth
93%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Adamis Pharmaceuticals Corp

Operating Income forecast
is not available for
Adamis Pharmaceuticals Corp

Net Income
Forecast

Net Income Estimate
Adamis Pharmaceuticals Corp

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
ADMP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADMP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADMP stock valuation using valuation multiples.
Wall Street Estimates
ADMP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADMP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ADMP's stock price target?
Price Target
0.42 USD

According to Wall Street analysts, the average 1-year price target for ADMP is 0.42 USD .

What is Adamis Pharmaceuticals Corp's Revenue forecast?
Projected CAGR
93%

For the last 1 year the compound annual growth rate for Adamis Pharmaceuticals Corp's revenue is 115%. The projected CAGR for the next 1 year is 93%.

ALPHA SPREAD
Join more than 135,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.